NHS guilty of ‘culture of cover-up', admits Streeting
The NHS is guilty of a 'culture of cover-up' over safety, the Health Secretary has admitted.
Wes Streeting said patients were being forced to endure situations that were 'totally intolerable', with concerns being dismissed when they attempted to find out the truth.
Mr Streeting said a 10-year health plan, due to be published within weeks, would have safety at its heart.
He made the comments after being tackled in the Commons about a case in which repeated NHS failings left a woman permanently disabled.
Perran Moon, a Labour MP, told him about the experience of his constituent, saying: 'A couple of weeks ago at my constituency surgery, through the tears, my constituent Amy explained how, following a hip operation in 2008, she suffered progressive nerve damage due to repeated failures in diagnosis, referral and treatment.
'Despite raising concerns for years, she was told her pain was common.'
The MP for Camborne and Redruth added: 'A nerve test in 2015 confirmed damage, and further tests last year showed a significant deterioration. After 17 years, she's only now been offered surgery.
'All Amy wants to know is what steps are being taken to ensure that no other patient is left permanently disabled due to such long and systemic failures.'
Responding, Mr Streeting said: 'Can I first of all, on behalf of the NHS, apologise to his constituent. That is a totally intolerable situation, but sadly not rare or exceptional.
'There's too much of that happening, and a culture of cover-up and covering reputations rather than being honest with patients about failures. We are changing the culture – safety is at the heart of the 10-year plan – and I'd be delighted to talk to him further about his constituent's case.'
The 10-year health plan follows promises for three major shifts in the way services are delivered – from hospital to community, from analogue to digital, and from treating sickness to prevention.
It comes after a record-breaking £29 billion annual cash injection for the health service in the spending review.
The plan will detail Mr Streeting's ambitions to turn the NHS into a 'neighbourhood health service' and to shift far more resources from hospitals into GP and community services.
He has also promised NHS league tables so there is no more 'turning a blind eye to failure', saying patients deserved 'far more transparency' about failings in the service.
Last month, the Government set out plans to hand out bonuses of up to £30,000 to health chiefs who deliver 'exceptional results' as part of efforts to turn NHS performance around.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
32 minutes ago
- Times
Alcohol labels should warn of cancer risk, urge health groups
Bottles of wine and beer should have warning labels stating that alcohol causes cancer, public health experts have said. The World Cancer Research Fund (WCRF), a charity based in London, has launched a campaign urging the government to require companies to put 'bold and unambiguous' health warnings and calorie information on alcoholic drinks. One in 25 cases of cancer in the UK — about 17,000 each year — are caused by alcohol, research shows. Alcohol can cause seven types of cancer, including breast and bowel. A group of health organisations have signed a letter to Sir Keir Starmer demanding a new 'national alcohol strategy', which would include mandatory product labelling. It is also calling for minimum alcohol pricing of 65p per unit in England — the level already in force in Scotland — as well as marketing and advertising restrictions on alcoholic drinks. The organisation said that this would reduce cancer risks as well as cutting other deaths from alcohol, after a 42 per cent increase in alcohol-specific deaths between 2019 and 2023. Alcohol has been shown to cause seven types of cancer OSCAR WONG/GETTY IMAGES Kate Oldridge-Turner, head of policy and public affairs at WCRF, said: 'The evidence is clear: health labelling on alcoholic drinks is urgently needed in the UK to help save lives. 'Health warning labels must be bold, unambiguous and completely separate from any marketing on the product. They should carry strong, clear messages about the health risks, which include the risk of cancer — far beyond vague advice like 'consume in moderation'. 'The goal must be to reduce alcohol use, given it increases the risk of seven types of cancer. Even if people continue to drink on social occasions, cutting down their regular intake would be a major step forward.' A poll of UK adults found that only one in 13 people knew that alcohol increases the risk of cancer and more people thought red wine had health benefits than knew of its cancer risk. Dr Helen Croker, assistant director of research and policy at WCRF, said: 'England prides itself on food safety, so why are our alcohol labelling and marketing restrictions far behind so many other countries? Why hasn't there been a national alcohol strategy in England since 2012? And why do bottles of beer show less information than bottles of orange juice? It is not mandatory in the UK to put health warnings on labels of alcoholic drinks MATTHEW HORWOOD/GETTY IMAGES 'We urgently need proper public awareness so that people understand the risks that come with drinking alcohol.' Sir Ian Gilmore, chairman of the Alcohol Health Alliance, said: 'One of the reasons public awareness is so low is that we are being kept in the dark about the true cost of drinking. People have the right to know the full picture so that they can make informed choices about what they consume. 'To reduce the impact of alcohol on our health, we need change at a national level. We urgently need a national alcohol strategy to open up honest conversations about the risks of alcohol, while putting measures in place to tackle and prevent its harms.'
Medical News Today
33 minutes ago
- Medical News Today
Rapamycin may extend lifespan as effectively as dietary restrictions
Research is ongoing about potential strategies to prolong life. A meta-analysis found that the drug rapamycin prolongs life in several vertebrate appeared to prolong life at a level similar to dietary restrictions. How to prolong life is a key area of scientific research. Experts are interested in medications that have the potential to boost longevity.A recent meta-analysis published in Aging Cell explored how rapamycin and metformin influenced longevity among several results confirmed that dietary restriction appears to prolong life and that rapamycin offers similar benefits. Researchers also found that metformin did not seem to prolong life. More research is required to see how rapamycin might help boost longevity in people. Rapamycin: Does it increase lifespan?In this paper, researchers note that decreasing food intake without malnourishment appears to prolong life but that this strategy is difficult for people to stick to. Thus, looking into possible medications that produce similar effects is an area of research. The two medications that were the focus of this analysis were rapamycin and metformin. According to the National Cancer Institute, rapamycin has a few functions, such as being an immunosuppressant and antibiotic, and it can help people who get helps with type 2 diabetes management. This analysis involved a systematic literature search to find relevant data. The final analysis included data from 167 papers looking at eight total vertebrate species, seeking to see how both medications affected longevity and how they compared to dietary extracted information on average and median lifespan from the papers. For this analysis, the two types of dietary restriction were caloric reduction and fasting, and researchers also sought to see if the results differed based on the sex of the animals involved. The data came from animals like mice, rats, turquoise killifish, and rhesus macaques. Overall, there were more males studied than females. There was also the most data on dietary restriction, and the most common type of dietary restriction was decreasing the number of calories. Regarding dietary restriction, the findings suggested great variation regarding the effects. Overall, researchers found that dietary restriction and rapamycin had a similar impact and appeared to contribute to prolonged life. Metformin appeared to only have a minimal impact on life from one metformin model, there appeared to be no consistent differences between male and female animals regarding longevity. Study author Zahida Sultanova, PhD, a Leverhulme Early Career Research Fellow with the University of East Anglia, in the United Kingdom summarized the key findings of the study to Medical News Today: 'We checked whether the two best-known 'diet-mimic' drugs increase lifespan similar to eating less in animals. By pooling data from 167 studies, we found that rapamycin is almost as reliable as eating less for increasing lifespan, whereas metformin is not. In other words, a compound that was extracted from soil bacteria 50 years ago seems able to copy many of the biological effects of a permanent diet, at least in lab animals.'Do the same benefits apply to people?This research analyzed animal data but did not include data about people. Additionally, most of these studies involved these animals in a laboratory setting and only looked at a small number of meta-analysis was also the work of only three researchers, sometimes with only one researcher doing a component of the work, which could have impacted the had the least amount of data on metformin, so more research about this medication might be helpful. They also operated under the assumption that if a paper did not specify male or female subjects, it was a mixed group, which could have been incorrect. The authors further note that the 'results were sensitive to how lifespan was reported.' Researchers also acknowledge strong publication bias and a lot of heterogeneity. Additionally, the type of measure used in study reporting affected results. In one measurement, the impact on life extension disappeared for the most part, the authors did not find a consistent difference in results based on the sex of the animals. They explain this could be because of 'differences in taxonomic groups studied […] and the calculated effect size.' Sultanova noted the following cautions regarding the findings: 'This study includes a high number of scientific studies conducted on different organisms such as mice, fish and monkeys. However, survival results in humans are not included because these drugs were not tested in humans for lifespan extension. Even if they are, the studies will take a long time considering the length of human lifespan. So, we do not recommend people to take rapamycin before the results of human trials consistently show that there are no side effects.'Why is it hard to study rapamycin in humans?Researchers suggest the need for research involving other species in natural and laboratory settings. They also note the need to understand the difference in impact for 'different strains of the same species exposed to the same treatment.'Future research can further focus on the differences between rapamycin and metformin and why they impact lifespan differently. More research into the differences in rapamycin's results in males and females could be helpful as well. More research can be done to see if rapamycin can promote prolonged life in people, but there may be some challenges in this Ali, MD, a board-certified general surgeon, bariatric surgeon, and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who was not involved in the study, told MNT that it 'shows the contribution of the immune system to lifespan, as rapamycin is an immunosuppressive medication.'According to him: 'The most logical next step is to explore the findings in humans; however, this would be a difficult study to design as rapamycin is a medication used in specific cancers and organ transplant and has significant side effects.'Despite this, the results show a potential benefit of rapamycin that warrants more explained that: 'Clinically, that puts rapamycin (and the mTOR pathway it targets) at the front of the queue for future anti-ageing therapies in humans. The compound had already been used for organ-transplant patients, so medical professionals understand its potential side effects.''The next step is waiting for the results of ongoing human trials that test lower and intermittent doses of rapamycin and refining the compound to 'rapalog' versions that keep the benefits while omitting side-effects such as immune suppression,' she told us.'Another important next step would be developing drugs that are similar in structure and function to rapamycin but without the side-effects. Scientists have already started refining rapamycin and producing the so-called rapalogs,' Sultanova noted.
The Guardian
43 minutes ago
- The Guardian
Vapes threaten to undo gains in tackling dangers of tobacco, health leaders warn
Aggressively marketed vapes threaten to undo progress made on smoking control, according to the World Health Organization. Officials, speaking at the World Conference on Tobacco Control in Dublin, said efforts were stalling when it came to helping tobacco users to quit, campaigning in the media on the dangers, and imposing higher taxes on tobacco products. Young people were particularly vulnerable, it added. Countries should consider extending the graphic health warnings already required on cigarette packets to vapes or e-cigarettes, heated tobacco products and nicotine pouches, the WHO said. In many countries, tobacco products had become more affordable in the past decade, the report said, despite a WHO recommendation that cigarettes should be taxed at 75%. While cigarettes became less affordable in 46 countries, they became more affordable in 42 others, including 23 low or middle-income countries. In 133 countries, vapes and similar devices are now regulated in some way – up from only eight in 2007. However, 62 countries apply no regulations at all. The extent of regulation varies, with almost 90% of wealthier countries either regulating or banning sales, compared with 66% of middle-income and only 27% of poor countries. In the UK, disposable vapes were banned this month in a bid to prevent young people using them and on environmental grounds. Dr Tedros Adhanom Ghebreyesus, WHO director general, said: 'Twenty years since the adoption of the WHO Framework Convention on Tobacco Control, we have many successes to celebrate, but the tobacco industry continues to evolve and so must we.' The report highlights nicotine pouches and heated tobacco products, as well as vapes, as examples of new products. Dr Rüdiger Krech, the WHO's director of health promotion, said they were 'aggressively marketed in ways that undermine hard-won public health gains'. He said national regulators could not be expected to deal with an onslaught of 'thousands' of new products, which represented an attempt by tobacco companies to focus attention away from their 'major business' of traditional tobacco. He added, however, that it was 'hugely important to regulate these new products, because they are attracting children and young people to actually use nicotine, and that's with the addiction that it brings', which he said would lead to tobacco use. Data is not available for all countries, but surveys suggest about 6% of children aged 13 to 15 use e-cigarettes. The WHO report on the global tobacco epidemic focuses on six tobacco control measures and rates countries on how far they have implemented them. These include taxation, introducing smoke-free air legislation, and offering smokers help to quit. Other measures include monitoring tobacco use and prevention policies, bans on tobacco advertising and sponsorship, and warning people about the dangers via pack labels and information campaigns. Since 2007, 155 countries have implemented at least one of the six measures at 'best-practice' level, the report found, with four countries – Brazil, Mauritius, the Netherlands and Turkey – implementing the full package. However, 40 countries have no measure at best-practice level, and more than 30 countries still allow cigarettes to be sold with no mandatory health warning. It means billions of people remain unprotected from the ill effects of tobacco, which claims kills more than 7 million people a year, the report warned. Alison Cox, director of policy and advocacy at the NCD [non-communicable disease] Alliance, said: 'It's clear that there is a long way to go if we are to reduce the many unnecessary tobacco related illnesses and premature deaths still occurring globally. 'Raising taxes is one of the most effective measures that offers governments a triple win of reducing tobacco consumption, saving lives and healthcare costs, while raising much-needed revenue.'
